says Brad Loncar of Loncar Investments Viva Biotech is the fourth largest company in China’s drug discovery services industry, with a 2.6 per cent market share. Photo: Bloomberg Viva Biotech’s hugely …
( read original story …)
Home BUSINESS Investors pile into Viva Biotech’s Hong Kong IPO as they are confident of the R&D services provider’s business model
ADVERTISEMENT
Categories
Beijing
22°
overcast clouds
humidity: 21%
wind: 1m/s SW
H 22 • L 20
Weather from OpenWeatherMap
Recent Posts
- China’s economy slows as trade war, weak demand highlight structural risks 20/10/2025
- Australia Courts US Backing To Break China’s Grip On Critical Minerals 20/10/2025
- Amazon Web Services outage sparks global issues, Trump lists China demands 20/10/2025
- WIPR’s China Trademarks Rankings 2025: New entries, hidden gems and big brands 20/10/2025
- Trump’s hand in the tariff war he started gets weaker as China GDP comes in ahead of growth forecasts 20/10/2025
- Senior Tory MPs urge Keir Starmer to block China ‘mega’ embassy plans 20/10/2025
- A trader’s guide to China’s biggest political meeting of 2025 20/10/2025
- China moves towards a new five-year plan, the planned system that went from the great famine to eradicating extreme poverty 20/10/2025
- China to draft new Five-Year plan as GDP growth hits one-year low 20/10/2025
- Chinese FM responds to rumors of financial troubles for Jakarta-Bandung High-Speed Railway project 20/10/2025
- Trump races to catch up to China’s rare earth dominance 20/10/2025
- China’s Rare-Earth Magnet Exports to US Slip Ahead of Trump-Xi 20/10/2025